Back to Search
Start Over
A novel model to predict cancer‐specific survival in patients with early‐stage uterine papillary serous carcinoma (UPSC)
- Source :
- Cancer Medicine, Vol 9, Iss 3, Pp 988-998 (2020), Cancer Medicine
- Publication Year :
- 2019
- Publisher :
- Wiley, 2019.
-
Abstract
- Objective Stage I‐II uterine papillary serous carcinoma (UPSC) has aggressive biological behavior and leads to poor prognosis. However, clinicopathologic risk factors to predict cancer‐specific survival of patients with stage I‐II UPSC were still unclear. This study was undertaken to develop a prediction model of survival in patients with early‐stage UPSC. Methods Using Surveillance, Epidemiology, and End Results (SEER) database, 964 patients were identified with International Federation of Gynecology and Obstetrics (FIGO) stage I‐II UPSC who underwent at least hysterectomy between 2004 and 2015. By considering competing risk events for survival outcomes, we used proportional subdistribution hazards regression to compare cancer‐specific death (CSD) for all patients. Based on the results of univariate and multivariate analysis, the variables were selected to construct a predictive model; and the prediction results of the model were visualized using a nomogram to predict the cancer‐specific survival and the response to adjuvant chemotherapy and radiotherapy of stage I‐II UPSC patients. Results The median age of the cohort was 67 years. One hundred and sixty five patients (17.1%) died of UPSC (CSD), while 8.6% of the patients died from other causes (non‐CSD). On multivariate analysis, age ≥ 67 (HR = 1.45, P = .021), tumor size ≥ 2 cm (HR = 1.81, P = .014) and >10 regional nodes removed (HR = 0.52, P = .002) were significantly associated with cumulative incidence of CSD. In the age ≥67 cohort, FIGO stage IB‐II was a risk factor for CSD (HR = 1.83, P = .036), and >10 lymph nodes removed was a protective factor (HR = 0.50, P = .01). Both adjuvant chemotherapy combined with radiotherapy and adjuvant chemotherapy alone decreased CSD of patients with stage I‐II UPSC older than 67 years (HR = 0.47, P = .022; HR = 0.52, P = .024, respectively). The prediction model had great risk stratification ability as the high‐risk group had higher cumulative incidence of CSD than the low‐risk group (P<br />Our prediction model of CSD based on proportional subdistribution hazards regression showed good performance in predicting the cancer‐specific survival of early‐stage UPSC patients and contributes to selection of adjuvant therapy for stage I‐II UPSC patients in clinical treatment strategy.
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_treatment
Kaplan-Meier Estimate
0302 clinical medicine
Risk Factors
Medicine
Cumulative incidence
Stage (cooking)
Original Research
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
prediction model
Treatment Outcome
Lymphatic Metastasis
030220 oncology & carcinogenesis
Uterine Neoplasms
Cohort
Female
medicine.medical_specialty
Clinical Decision-Making
Hysterectomy
Risk Assessment
lcsh:RC254-282
Disease-Free Survival
Decision Support Techniques
nomogram
03 medical and health sciences
Internal medicine
cancer‐specific death (CSD)
Adjuvant therapy
Humans
competing risk model
Radiology, Nuclear Medicine and imaging
Risk factor
Aged
Neoplasm Staging
Proportional Hazards Models
business.industry
Clinical Cancer Research
Chemoradiotherapy, Adjuvant
Nomogram
United States
Cystadenocarcinoma, Serous
uterine papillary serous carcinoma (UPSC)
Radiation therapy
Nomograms
030104 developmental biology
Lymph Node Excision
Lymph Nodes
business
Decision Making, Shared
Follow-Up Studies
SEER Program
Subjects
Details
- ISSN :
- 20457634
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Cancer Medicine
- Accession number :
- edsair.doi.dedup.....5b28744380d3dfff61a9b4b565ff6637
- Full Text :
- https://doi.org/10.1002/cam4.2648